Look at how much the insider officers have sold. A lot. It is hard to believe this stock worth so much because it has only one small product in p3, which is LAL, and Glybera has already been approved in europe; all other candidates are in preclinical stage. should be at $10-20 range.
Sentiment: Strong Sell